Product Name: IgG4 Antibody [IGHG4/1345]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P, WB
Applications: Flow Cytometry: 0.5-1ug/10^6 cellsIF: 1-2 ug/mlWB: 0.5-1 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 min at RTThe concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the IgG4 antibody to be titered up or down for optimal performance.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: A human recombinant protein corresponding to the Fc region was used as the immunogen for this IgG4 antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 51940-44-4
Product: (+)-Bicuculline
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names:
Accession NO.:
Protein Ino:
Official Symbol: IGHG4
Geneid: 3503
Background: The regions of relatively constant sequence beyond the variable regions of immunoglobulins are termed constant regions (C regions) and are present in both the heavy and light chains. With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are located in these C regions. These regions also function to hold the variable regions together by using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells.
PubMed ID:http://aac.asm.org/content/25/5/599.abstract
